Liposarcoma medical therapy

Liposarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Liposarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Liposarcoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Liposarcoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Liposarcoma medical therapy
CDC on Liposarcoma medical therapy
Liposarcoma medical therapy in the news
Blogs on Liposarcoma medical therapy
Directions to Hospitals Treating Liposarcoma
Risk calculators and risk factors for Liposarcoma medical therapy

Drugs	Dose
Doxurubicin	Doxurubicin 75 mg/m2; 28 day cycle
Pegylated liposomal doxurubicin	40-50 mg/m2 ; 28 day cycle